Luye Pharma USA is showcasing Rykindo at APA 2026. Here's the context, what to ask at the booth, and where Videra fits in the conversation.
Similar to Erzofri — Rykindo competes in the LAI space for schizophrenia and adds a bipolar maintenance indication. Biweekly dosing vs. monthly creates a different adherence profile.
Ask about: Bipolar maintenance data and uptake; biweekly vs. monthly preference among prescribers; combined Erzofri + Rykindo market strategy.
Same ePRO+/VoiceVitals story as Erzofri — between-injection monitoring. Biweekly dosing means more frequent touchpoints where Videra data informs clinical decisions.
Set up a follow-up with Luye Pharma USA's team and Videra Health.
Email Ryan Roberts →